What is the YELLOWSTONE program?

The YELLOWSTONE clinical research program will help determine whether the investigational medication ozanimod is safe and effective for the treatment of moderately to severely active Crohn’s disease. Having active disease means you are currently experiencing symptoms associated with Crohn’s disease.

• YELLOWSTONE is comprised of several clinical trials.
• The Induction 1 and 2 studies are the first phase 3 studies and are currently accepting new Crohn’s disease patients.
• The Maintenance study will only accept patients who have completed either the Induction 1 or Induction 2 study.
• Crohn’s disease patients may also have the opportunity to enroll in an Open-label study.
• For each study, you can expect to have visits with a doctor every 1-3 months. The length of each visit may vary.
• You may stop participating in either study at any time.